Odyssey Therapeutics files for IPO, seeks to list on Nasdaq under ticker 'ODTX'
Initial Public Offering: Odyssey Therapeutics has filed for an initial public offering (IPO) with the SEC, seeking to list its common stock on the Nasdaq under the symbol "ODTX."
Clinical Programs: The company is focused on developing treatments for autoimmune and inflammatory diseases, with advanced programs including a Phase 2a trial for ulcerative colitis and two preclinical programs targeting specific proteins.
Trade with 70% Backtested Accuracy
Analyst Views on ODTX
No data
About the author
ODYSSEY THERAPEUTICS INC INCREASES IPO TO 15.5 MILLION SHARES, SETTING PRICE AT $18.00 EACH
Company Overview: Odysssey Therapeutics has announced a significant upsizing of its initial public offering (IPO).
IPO Details: The company is offering 15.5 million shares at a price of $18.00 per share.
ODYSSEY THERAPEUTICS REVEALS PRICING FOR LARGER INITIAL PUBLIC OFFERING
Company Announcement: Odysssey Therapeutics has announced the pricing of its upsized initial public offering (IPO).
IPO Details: The IPO will involve a larger number of shares being offered to the public than initially planned.
ODYSSEY THERAPEUTICS INC INCREASES IPO TO 15.5 MILLION SHARES, SETTING PRICE AT $18.00 EACH
Company Overview: Odysssey Therapeutics has announced a significant upsizing of its initial public offering (IPO).
IPO Details: The company is offering 15.5 million shares at a price of $18.00 per share.
ODYSSEY THERAPEUTICS REVEALS PRICING FOR LARGER INITIAL PUBLIC OFFERING
Company Announcement: Odysssey Therapeutics has announced the pricing of its upsized initial public offering (IPO).
IPO Details: The IPO will involve a larger number of shares being offered to the public than initially planned.
